Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Equity Average (2016 - 2026)

Iradimed has reported Equity Average over the past 13 years, most recently at $96.6 million for Q1 2026.

  • Quarterly Equity Average rose 9.19% to $96.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $96.6 million through Mar 2026, up 9.19% year-over-year, with the annual reading at $90.7 million for FY2025, 14.66% up from the prior year.
  • Equity Average was $96.6 million for Q1 2026 at Iradimed, roughly flat from $96.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $96.6 million in Q1 2026 and troughed at $64.2 million in Q2 2022.
  • The 5-year median for Equity Average is $73.8 million (2024), against an average of $78.8 million.
  • Year-over-year, Equity Average increased 0.36% in 2022 and then grew 19.88% in 2025.
  • A 5-year view of Equity Average shows it stood at $71.7 million in 2022, then increased by 1.77% to $73.0 million in 2023, then increased by 16.62% to $85.1 million in 2024, then grew by 13.34% to $96.5 million in 2025, then grew by 0.08% to $96.6 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Equity Average are $96.6 million (Q1 2026), $96.5 million (Q4 2025), and $96.3 million (Q3 2025).